Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer

Jie Deng | Xuejiao Ma | Yang Ni | Xiaomin Li | Wenjing Xi | Minqi Tian | Xing Zhang | Manyu Xiang | Wanglong Deng | Chao Song | Hao Wu

1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
2State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, Jiangsu, China
3Department of Medicine, Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, Jiangsu, China

Correspondence
Hao Wu, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, PR China.
Email: wuhaodoc1979@163.com

Background: The breakthrough of immunotherapy has revolutionized the treatment of non-small cell lung cancer (NSCLC). However, only a limited part of patients could derive clinical benefits. To study how immune microenvironment (IME) of patients could influence the therapeutic efficacy of immunotherapy, we evaluated the response patterns of NSCLC patients treated with PD-1 inhibitors and analyzed the molecules related to prognosis and efficacy of immunotherapy.

Methods: Tumor samples were collected from 47 NSCLC patients treated with PD-1 inhibitors. RNA expressions of tumor immune-related 289 genes were analyzed using NanoString nCounter. Immune infiltration and correlation between clinical information and expression of immune-related genes were assessed.

Results: Unsupervised clustering analysis revealed two groups infiltrated with different immune cells and differentially expressed genes (DEGs) including CXCL5, CXCL9, IDO1, and LAG3 were found between groups. Stratification based on DEGs indicated that the group with high expression of CXCL5 was characterized by neutrophils. Univariate and multivariate Cox analysis further demonstrated that CXCL5 mRNA expression was positively associated with worse progression free survival (PFS). Logistic analyses indicated high CXCL5 was associated with worse response to immunotherapy.

Conclusions: CXCL5 may be a potential biomarker for prognosis and responsiveness to immunotherapy and may be a novel preventive and therapeutic target for NSCLC.

KEYWORDS
biomarker, CXCL5, immunotherapy, non-small cell lung cancer, tumor microenvironment

INTRODUCTION

Lung cancer is the second most frequent cancer and remains the leading cause of cancer-related death, with approximate 2.2 million new cases and 1.8 million deaths worldwide in 2020 and about 85% cases are diagnosed with non-small cell lung cancer (NSCLC), which usually does not show obvious clinical symptoms until in the
late stage. Delayed diagnosis with advanced disease leads to a low 5-year survival rate of less than 15%.3

Since nivolumab and pembrolizumab as the blockade of programmed cell death-1 (PD-1) were approved by US Food and Drug Administration in 2015, immune checkpoints inhibitors (ICIs) have brought a new era of immunotherapy in NSCLC.4 In several clinical trials ICIs demonstrated improvement in overall survival (OS) in a limited number of patients either as monotherapy or combined with chemotherapy.5-7 When taken programmed death ligand 1 (PD-L1) expression on more than 50% tumor cells as preselection, the objective response rate to immunotherapy was still lower than 50% in NSCLC.8 And “low” PD-L1 expression (<1% tumor proportion score) could not totally exclude the patients who benefited from ICIs. Various predictive biomarkers have been explored like tumor mutational burden (TMB),9 driver gene mutations,10 but none have been enough validated to discriminate the patients sensitive to ICIs in clinical application.

Tumor microenvironment (TME) is a promising area of research with studies suggesting immune gene signatures as biomarkers for prognosis and response to ICIs. High levels of tumor infiltration lymphocytes (TILs) containing CD3+, CD4+, and CD8+ are associated with prolonged survival in NSCLC.11 Some studies concentrating on interferon gamma (IFNγ) relate to mRNA signatures, which are involved in many processes of immune responses and predictive for a higher efficacy of ICIs.12,13 Some gene expression signatures related to immune genes also show their potential utility as biomarkers in immunotherapy.14-16

In an attempt to understand the complex IME in NSCLC patients treated with ICIs and discover more explicit predictive biomarkers, we evaluated the response patterns of these patients and analyzed the molecules related to prognosis and efficacy of immunotherapy.

2 | MATERIALS AND METHODS

2.1 | Patients

This study included the patients treated with anti-PD-1 as monotherapy or combined with chemotherapy from The First Affiliated Hospital of Nanjing Medical University between October 2018 and February 2020. Written informed consent was obtained from all patients before enrollment and study protocol was approved by the Institutional Review Board of The First Affiliated Hospital of Nanjing Medical University (No. 2021-N1-13). Clinicopathologic features and treatment histories of patients were extracted from medical records. Samples with failed quality control (QC) or patients evaluated as stable disease for less than 24 weeks follow-up were excluded.

2.2 | RNA sequencing and data processing

All tumor samples were acquired before anti-PD-1 treatment and preserved formalin-fixed paraffin-embedded slides. Gene expression was measured using the nCounter platform (NanoString Technologies) and transcriptome analysis was based on the 289-immuno-gene panel. This panel allows simultaneous analysis of 289 genes involved in the immune response in cancer. For each sample, QC indicators included the imaging QC, binding density QC, positive control linearity QC and positive control limit of detection QC. Positive normalization factor and content normalization factor were then calculated. Samples qualified for QC were included in subsequent analysis. The raw data of each sample and genes were standardized against internal controls to eliminate technical variability in the assay, and then counts were normalized to the geometric mean of endogenous housekeeping genes followed by log2 transformation.

2.3 | Estimation of TME cell infiltration

Marker genes of 14 immune cell types, including B-cells, dendritic cells, macrophages, exhausted CD8 T cells, CD8 T cells, neutrophils, mast cells, cytotoxic cells, Treg, natural killer CD56dim cells, NK cells, CD45, and Th1 cells were retrieved from the method previously reported.15,17,18 We further divided the macrophages into M1 and M2 macrophages according to the previous reports.19,20 The role of M1 macrophages is to secrete pro-inflammatory cytokines and chemokines, present antigens, participate in a positive immune response and act as an immune monitor. M2 macrophages can reduce inflammation, promote tumor growth, and immunosuppress. All TME cell infiltration scores were calculated as the arithmetic mean of constituent genes.

2.4 | Generation of TME signatures

We constructed a set of gene sets that stored genes associated with some biological processes, including cytotoxic T lymphocyte (CTL) levels, cytolytic activity (CYT) score, chemokines, T cell markers, total TIL score, Teff score, IFN-γ signature, and GEP score. The CYT score of each sample was evaluated based on the geometric mean of the product of PRF1 and GZMA genes.14 GEP score was calculated as a weighted linear average of the constituent genes,13,15 and the remaining TME signatures were calculated as the arithmetic mean of corresponding genes.12,15,16,22,23
2.5 | Unsupervised consensus clustering

In this study, we used nonnegative matrix factorization of R package to virtually dissect the RNA expression profiles of 47 patients and extract the immune–related expression pattern to characterize the immune landscape of NSCLC.\textsuperscript{24} The value of k where the magnitude of the cophenetic correlation coefficient began to fall was chosen as the optimal number of clusters (Figure S1). We classified the patients into two groups based on the immune expression, namely the TMECluster1 and TMECluster2. The number of clusters and their stability were determined by the consensus clustering algorithm. We used the ConsensusClusterPlus package to perform the above steps and 200 times of repetitions were conducted for guaranteeing the stability of classification.\textsuperscript{25}

2.6 | Identification of DEGs between different clusters

To identify immune-related genes, we classified the patients into two distinct TME Clusters, namely the DEGCluster1 and DEGCluster2. The empirical approach of limma and edgeR package was applied to determine DEGs between the two TME Clusters.\textsuperscript{26,27} Specifically, according to the read count of the sample, the TMM standardization method of the calcNormFactors function in the edgeR package was used. After log-transform, the limma-trend method in the limma package was employed for differential analysis using the Benjamini–Hochberg method. The significant criteria for determining DEGs was set as \( p \) values <0.05 and expression fold change (FC) ≥2 or ≤1/2.

2.7 | Evaluation of the efficacy

Time from the first day of immunotherapy to progression or the last time of follow-up was considered as progression-free survival (PFS). The clinical response was estimated in accordance with the response evaluation criteria in solid tumors.\textsuperscript{28} In our study, the patients with complete response, partial response, and stable disease for at least 24 weeks after use of anti-PD-1 agents were defined as responders, while those with progressive disease were as nonresponders.

2.8 | Statistical analysis

The unpaired \( t \) test was used to compare the estimated immune cell types and immune signature scores between two groups. Survival analyses were performed with Kaplan–Meier curves and log-rank test. Univariate and multivariate Cox proportional hazard regression models were constructed to adjust for confounding variables including age, gender, TNM-based staging, and expression of DEGs. To test the correlation between responsiveness to anti-PD-1 agents and variables, a logistic regression model was used.

| TABLE 1 Baseline characteristics of patients (\( n = 47 \)) |
| Characteristics | All, \( n \) (%) | Stage III, \( n \) (%) | Stage IV, \( n \) (%) | \( p \) value |
|-----------------|-----------------|-----------------|-----------------|--------------|
| \( N^{a} \)     | 47 (100)        | 12 (26)         | 33 (70)         |              |
| Age, years      |                 |                 |                 |              |
| Median (range)  | 67 (43–81)      | 66.5 (55–81)    | 67 (43–80)      | 0.738        |
| Sex             |                 |                 |                 |              |
| Female          | 8 (17)          | 1 (8)           | 6 (19)          | 0.655        |
| Male            | 39 (83)         | 11 (92)         | 27 (81)         |              |
| Smoking         |                 |                 |                 |              |
| Never smoker    | 16 (34)         | 3 (25)          | 12 (36)         | 0.051        |
| Former smoker   | 24 (51)         | 4 (33)          | 19 (58)         |              |
| Current smoker  | 6 (13)          | 4 (33)          | 2 (6)           |              |
| NA              | 1 (2)           | 1 (8)           | 0               |              |
| Pathology       |                 |                 |                 |              |
| LUAD            | 18 (38)         | 2 (17)          | 15 (45)         | 0.090        |
| LUSC            | 28 (60)         | 10 (83)         | 17 (52)         |              |
| NA              | 1 (2)           | 0               | 1 (3)           |              |
| ECOG            |                 |                 |                 |              |
| 0               | 15 (32)         | 5 (42)          | 10 (30)         | 0.796        |
| 1               | 30 (64)         | 7 (58)          | 22 (67)         |              |
| 2               | 1 (2)           | 0               | 1 (3)           |              |
| NA              | 1 (4)           | 0               | 0               |              |
| Immunotherapy   |                 |                 |                 |              |
| Monotherapy     | 11 (23)         | 2 (17)          | 9 (27)          | 0.168        |
| Combined with chemotherapy | 36 (77)     | 10 (83)        | 24 (73)         |              |
| Drug            |                 |                 |                 |              |
| Camrelizumab    | 13 (28)         | 3 (25)          | 8 (24)          | 0.565        |
| Nivolumab       | 11 (23)         | 1 (8)           | 10 (30)         |              |
| Pembrolizumab   | 9 (19)          | 3 (25)          | 6 (19)          |              |
| Toripalimab     | 7 (15)          | 2 (17)          | 5 (15)          |              |
| Sintilimab      | 7 (15)          | 3 (25)          | 4 (12)          |              |

Abbreviations: ECOG, Eastern Cooperative Oncology Group; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NA, not available.

\( ^{a} \)Two patients with unknown stage were excluded. \( p \) values were based on Fisher’s exact test or Mann–Whitney test.
All statistical analyses were performed using R package (version 3.5.1) and SPSS software (version 22.0, Chicago, IL). Boxplots were generated in R with the ggplot2 package, indicating median and interquartile range. Statistical tests were two-sided and with p value <0.05 taken as statistical significance.

3 | RESULTS

3.1 | Patient characteristics

After exclusion of three patients with unqualified samples and four SD patients with less than 24 weeks follow-up time, a total of 47 eligible patients were analyzed in the study (Table 1). The median follow-up was 11 months (range, 0 to 31 months). Patients were 43–81 years old and with a male predominance. Eleven of 47 patients (23%) were treated with anti-PD-1 agents as monotherapy and the rest (77%) received immunotherapy combined with chemotherapy. There were 12 patients with stage III, 33 with stage IV, and 2 with unknown stage. Based on TNM staging, the patients were divided into two groups except for those with unknown stage. The results showed no differences between these two groups in baseline characteristics (all p > 0.05; Table 1).

3.2 | TME subtypes

To discriminate different patterns of TME, we performed an unsupervised consensus clustering based on 14 immune infiltration cell types (Figure 1A). The results revealed the cluster number of two was optimal (TMECluster1: n = 25; TMECluster2: n = 22) and microenvironment cell infiltration and immune signatures of the two clusters were demonstrated in Figure 1B. TMECluster1 was poor in TILs like B cells, T cells, and NK cells, with low levels of immune signatures, whereas TMEcluster2 was characterized by high infiltration in cytotoxic cells, chemokines, and high CYT scores and total TIL scores Figure 1C. Through differential expression analysis between the two clusters, four DEGs including CXCL5, IDO1, CXCL9, and LAG3 were acquired.
3.3 | DEG-based subtypes

Unsupervised clustering analysis of expression of four DEGs was utilized to stratify patients into two clusters, DEGCluster 1 (n = 18) and DEGCluster 2 (n = 29). The matching rate of the TMEClusters and DEGClusters was 48.0% and 72.7% for DEGCluster1 and DEGCluster2 (Figure 2A).

We further investigated the differences in the immune microenvironment between two clusters. The immune and cell type scores were measured to quantify the infiltration of immune cells in tumors. DEGCluster2 was characterized by relatively high immune scores related to cytolytic activity, chemokines, T cells, TILs, and IFNγ signatures (Figure 2C). Higher abundance of CD45 cells, cytotoxic cells, and exhausted CD8 cells, but lower levels of neutrophils were observed in DEGCluster2 (Figure 2D). And Cluster2 exhibited superior survival (Figure 2B).

3.4 | Association between expression of DEGs and PFS

Using the Kaplan–Meier method, a statistically significant longer PFS was shown for patients with lower CXCL5 expression (p = 0.017) (Figure 3A). On the contrary, patients with higher expression of CXCL9, LAG3 had a prolonged PFS (p = 0.012 and <0.001, respectively) (Figure 3B,C). However, no significant correlation was observed between expression of IDO1 and PFS (p = 0.3) (Figure 3D).

To further investigate the association between PFS and other clinicopathological variables, univariate and multivariate Cox proportional hazards models were constructed. The univariate analysis showed the expression of CXCL5 (p < 0.001), IDO1 (p = 0.022), CXCL9 (p = 0.019), and LAG3 (p = 0.002) was statistically associated with survival. After adjusting for clinical factors including age, sex, and TNM stage, multivariable analyses revealed that expression of
CXCL5 (hazard ratio: 1.791, 95%CI: 1.232–2.603; \( p = 0.003 \)) was an independent prognostic factor for PFS (Table 2).

### 3.5 Predictive signatures in response

After identification of prognostic value of CXCL5 expression, we conducted Logistic regression analyses to further evaluate different variables in predicting response. According to assessment to anti-PD-1 treatment, the response rate was 70.2%. There was a correlation between response to ICI treatment and expression of CXCL5 (Odds ratio: 0.5, 95%CI: 0.22–0.89, \( p = 0.05 \)) (Figure 4A).

The receiver operating characteristic curve was drawn based on whether the expression of CXCL5 was used as

---

**FIGURE 3** Kaplan–Meier survival analysis for high- and low expression of (A) CXCL5, (B) CXCL9, (C) LAG3, and (D) IDO1

**TABLE 2** Univariate and multivariate Cox analysis of the expression of DEGs and clinicopathological characteristics

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|----------------------|
|           | HR                  | 95% CI               | \( p \) value | HR                  | 95% CI               | \( p \) value |
| Age       | 1.035               | 0.971–1.103          | 0.295        | 1.022               | 0.941–1.108          | 0.607        |
| Gender    | Male vs. female     | 1.401                | 0.313–6.268  | 0.659               | 1.838               | 0.112–30.206 | 0.670        |
| TNM       | IV vs. III          | 2.213                | 0.490–9.995  | 0.302               | 3.178               | 0.526–19.193 | 0.208        |
|           | CXCL5               | 1.829                | 1.353–2.473  | 0.001               | 1.791               | 1.232–2.603 | 0.003        |
|           | IDO1                | 0.532                | 0.310–0.915  | 0.022               | 0.535               | 0.279–1.027 | 0.060        |
|           | CXCL9               | 0.635                | 0.435–0.927  | 0.019               | 0.873               | 0.408–1.867 | 0.726        |
|           | LAG3                | 0.405                | 0.230–0.715  | 0.002               | 0.823               | 0.359–1.887 | 0.646        |

Abbreviations: HR, hazard ratio; CI, confidence interval.

\(^* p < 0.05.\)
a predictor for short-term benefit (dichotomy of response and nonresponse). The area under the curve was 0.81 with the optimal cutoff value of 8.92. The specificity was 78.57% and the sensitivity was 78.79%, implying a moderately high ability of the CXCL5 expression to predict the response to immunotherapy.

4 | DISCUSSION

In this analysis, we performed a comprehensive analysis of TME to identify immune-related biomarkers to predict the responsiveness to immunotherapy and prognosis of NSCLC patients. Based on immune scores and DEGs we divided the patients into two clusters and compared the difference of immune components between them. The results found that an upregulation of expression of CXCL5 was an independent predictor for poor prognosis and unfavorable response to ICIs.

Innate and adaptive immune cells play an essential role in TME remodeling and could be predictors for clinical outcomes.29 The effect of TILs on prognosis is controversial since they may participate in tumor-promoting or tumor-suppressing activities which lead in the different stages of tumor progression. High levels of TILs are mainly correlated with better outcomes.30 CD8+ cytotoxic T cells evoke the tumor destroying by releasing IFNγ and other factors, and there is a positive correlation between high infiltration of CD8+ lymphocytes and prolonged survival in NSCLC.31 Consistent with our results an increased inflammatory microenvironment has been shown higher level of cytotoxic cells and higher score of IFNγ signature in DEGCluster2, which demonstrated favorable PFS. And enriched exhausted CD8+ cells in the same group could be explained by persistent antigenic stimulation.32

CXCL5, a pro-inflammatory cytokine, belonged to the CXC-type chemokine family, which was secreted by tumor or tumor infiltrating immune cells and regulated the TME.34,35 Combined with chemokine receptor 2 (CXCR2), CXCL5 participated in recruiting leukocytes, proliferating tumor cells, and metastasis. CXCL5 promotes cell proliferation and migration by activating the downstream MAPK/ERK1/2 and PI3K/AKT signaling pathways, in which activation of AKT and ERK1/2 has influence on the elevated activity of neutrophils in NSCLC.36 Tumors with high expression of CXCL5 were highly infiltrated with T cells and macrophages, which took part in immune responses.37 Besides NSCLC, several previous studies showed that increased expression level of CXCL5 was an adverse prognosis biomarker in pancreatic cancer, hepatocellular carcinoma, and bladder cancer.38–40 Congruously, we found that the high expression of CXCL5 group was enriched in neutrophils and demonstrated shorter PFS. In addition, a negative correlation between CXCL5 expression and response to anti-PD-1 agents was proved.

To the best of our knowledge, we first reported the CXCL5 expression level as an independent factor for responsiveness to ICIs. The results were validated in another cohorts with lung cancer treated with immunotherapy.41 A higher responder rate was observed in the patients with low CXCL5 expression levels compared with high expression levels, but the difference was statistically insignificant due to the limited sample size, suggesting that CXCL5 expression might be a potential predictive and prognostic biomarker for immunotherapy in NSCLC. Currently, CXCL5 has also been proved to contribute to angiogenesis and proliferation, promoting malignant progression in distinct cancers.37 CXCL5 expression was positively associated with the risk of metastasis in bladder cancer, NSCLC,
In conclusion, our study found a novel prognosis-related gene clustering based on four genes, CXCL5, LAG3, IDO1, and CXCL9. This clustering was associated with tumor immune infiltration. Furthermore, increased CXCL5 expression was related to unfavorable survival and poor responsiveness to ICIs. Therefore, CXCL5 is likely to exert a crucial impact on TME and has the potential to act as a prognostic biomarker for prognosis and response to immunotherapy in NSCLC.

CONFLICT OF INTEREST
The authors declare that they have no competing interest.

AUTHOR CONTRIBUTIONS
J. Deng and H. Wu were responsible for study conception. J. Deng, X. Ma, and Y. Ni wrote the original draft. X. Li, W. Xi, W. Deng, and X. Zhang analyzed and interpreted the data. M. Tian, M. Xiang, and C. Song participated in sample collection and investigation. H. Wu reviewed and edited the manuscript. All the authors read and approved the final manuscript.

CONSENT FOR PUBLICATION
Written informed consent was obtained from all patients before enrollment.

DATA AVAILABILITY STATEMENT
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The study protocol was approved by the Institutional Review Board of The First Affiliated Hospital of Nanjing Medical University (No. 2021-NT-13).

ORCID
Hao Wu https://orcid.org/0000-0002-4033-3665

REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
2. Judd J, Borghaei H. Combining immunotherapy and chemotherapy for non-small cell lung cancer. Thorac Surg Clin. 2020;30:199-206.
3. Lin A, Wei T, Meng H, Luo P, Zhang J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 2019;18:139.
4. Villanueva N, Bazhenova L. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis. 2018;12:175346618794133.
5. Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29:959-965.
6. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.
7. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-2092.
8. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
9. Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22:4585-4593.
10. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2016;378:2078-2092.
11. Zeng DQ, Yu YF, Ou QY, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget. 2016;7:13765-13781.
12. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837-1846.
13. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930-2940.
14. Danaher P, Warren S, Dennis L, et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017;5:18.
15. Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550-1558.
16. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782-795.
18. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453-457.
19. Germano G, Frapolli R, Belgiojone C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23:249-262.
20. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958-969.
21. Damotte D, Warren S, Arrondeau J, et al. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. J Transl Med. 2019;17:357.
22. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486-499.
23. McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24:749-757.
24. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci USA. 2004;101:4164-4169.
25. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572-1573.
26. Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
27. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-140.
28. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
29. Altorki NK, Markowitz GI, Gao D, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19:9-31.
30. Badalamenti G, Fanale D, Incorvaia L, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone? Cell Immunol. 2019;343:103753.
31. Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015;107:dju435.
32. Kim MY, Koh J, Kim S, Go H, Jeon YK, Chung DH. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of onecogenic drivers. Lung Cancer. 2015;88:24-33.
33. Thommen DS, Koelzer VH, Herzig P, et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24:994-1004.
34. Zhu J, Zhou Y, Wang L, et al. CXCL5/CXCL8 is a promising potential prognostic and tumor microenvironment-related cluster in hepatocellular carcinoma. J Gastrointest Oncol. 2020;11:1364-1380.
35. Chen X, Chen R, Jin R, Huang Z. The role of CXCL chemokine family in the development and progression of gastric cancer. Int J Clin Exp Pathol. 2020;13:484-492.
36. Wang L, Shi L, Gu J, et al. CXCL5 regulation of proliferation and migration in human non-small cell lung cancer cells. J Physiol Biochem. 2018;74:313-324.
37. Zhang W, Wang H, Sun M, et al. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun. 2020;40:69-80.
38. Li A, King J, Moro A, et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol. 2011;178:1340-1349.
39. Zhou SL, Dai Z, Zhou ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;56:2242-2254.
40. Zhu X, Qiao Y, Liu W, et al. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients. Tumour Biol. 2016;37:4569-4577.
41. Prat A, Navarro A, Paré L, et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 2017;77:3540-3550.
42. Wu K, Yu S, Liu Q, Bai X, Zheng X, Wu K. The clinical significance of CXCL5 in non-small cell lung cancer. Onco Targets Ther. 2017;10:5561-5573.
43. Soler-Cardona A, Forsthuber A, Lipp K, et al. CXCL5 facilitates melanoma cell-neutrophil interaction and lymph node metastasis. J Invest Dermatol. 2018;138(7):1627-1635.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Deng J, Ma X, Ni Y, et al. Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer. Cancer Med. 2022;11:1787–1795. doi: 10.1002/cam4.4567